Condition: Gastric Cancer · MSI-H · Metastatic Cancer · Sponsor: Centre Leon Berard
CIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a bi-immunotherapy (experimental arm) versus standard current treatment (FOLFOX/XELOX + nivolumab : standard arm).
This description comes directly from the study's public registry record.
Christelle DE LA FOUCHARDIERE, MD · 04 91 22 35 03 · delafouchardierec@ipc.unicancer.fr
Always discuss trial participation with your own doctor first.
| CHU de Brest | Brest, France | Recruiting |
| CHU de Clermont-Ferrand | Clermont-Ferrand, France | Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Hôpital Privé Jean Mermoz | Lyon, France | Recruiting |
| Institut Paoli Calmettes | Marseille, France | Recruiting |
| Institut Mutualiste Montsouris | Paris, France | Recruiting |
| CHU de Poitiers | Poitiers, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06346197